This idea was supported by data about MDA-MB- 231, triple negative breast cancer cell line, that Fulvestrant has no MDM2 effect on proliferation in the absence of estrogen receptor activation (Kundu et al. 2017), which confirms that alizarin mainly works by cutting off estrogenic signals. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.